Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: J Surg Res. 2014 Jul 2;192(2):254–262. doi: 10.1016/j.jss.2014.06.054

[A] [³H]-thymidine incorporation of cultured human coronary vascular smooth muscle cells in response to CTF [10 nM], EGF [10 μg/mL] and HB-EGF [10 μg/mL] in the presence and absence of the EGFR inhibitor [AG1478]. Values are the mean±s.e.m. fold increase over control for five experiments [* p<0.05, **p<0.01].

[B] Cell proliferation of cultured human coronary vascular smooth muscle cells over a seven-day period in response to CTF [10 nM] in the presence and absence of the EGFR inhibitor [AG1478]. Values are the mean±s.e.m. fold increase over control for five experiments [**p<0.01 vs DMEM control].

[A] [³H]-thymidine incorporation of cultured human coronary vascular smooth muscle cells in response to CTF [10 nM], EGF [10 μg/mL] and HB-EGF [10 μg/mL] in the presence and absence of the EGFR inhibitor [AG1478]. Values are the mean±s.e.m. fold increase over control for five experiments [* p<0.05, **p<0.01].

[B] Cell proliferation of cultured human coronary vascular smooth muscle cells over a seven-day period in response to CTF [10 nM] in the presence and absence of the EGFR inhibitor [AG1478]. Values are the mean±s.e.m. fold increase over control for five experiments [**p<0.01 vs DMEM control].